On ECHEMI
Home > Drugs > Changzhou Lanling Pharmaceutical Co., Ltd.
Changzhou Lanling Pharmaceutical Co., Ltd.
  • Founded in:

    1979-01-01
  • Country:

    China China
  • Address:

    No. 352, Laodong East Road, Changzhou
  • Tax NO.:

    91320400137158984C
  • Registered Funds:

    25 million yuan
  • Website:

  • Email:

Related Drugs
Clindamycin Hydrochloride Capsules
The main ingredient of this product is clindamycin hydrochloride.
Name Description Content CAS NO. Registered Holders
Clindamycin hydrochloride

The antibacterial spectrum is the same as that of lincomycin, and the antibacterial activity is 4 to 8 times stronger than that of lincomycin. It has high antibacterial activity against aerobic Gram-positive cocci, such as Staphylococcus (including penicillin-resistant and methicillin-sensitive strains), hemolytic streptococci, grass-green streptococci, and Streptococcus pneumoniae. It also has good antibacterial effects on anaerobic bacteria. Most of the genera, such as Bacteroides, Fusobacterium, Actinomyces, Peptococci, and Peptostreptococci are sensitive to this product. It acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria.

More

The antibacterial spectrum is the same as that of lincomycin, and the antibacterial activity is 4 to 8 times stronger than that of lincomycin. It has high antibacterial activity against aerobic Gram-positive cocci, such as Staphylococcus (including penicillin-resistant and methicillin-sensitive strains), hemolytic streptococci, grass-green streptococci, and Streptococcus pneumoniae. It also has good antibacterial effects on anaerobic bacteria. Most of the genera, such as Bacteroides, Fusobacterium, Actinomyces, Peptococci, and Peptostreptococci are sensitive to this product. It acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria.

21462-39-5 34
Aminophylline Injection
Aminophylline
Name Description Content CAS NO. Registered Holders
Aminophylline

It has a direct relaxant effect on respiratory smooth muscle, inhibits phosphodiesterase to increase the intracellular cAMP content, achieves bronchial dilation partly by releasing endogenous adrenaline and norepinephrine, can enhance the contractility of the diaphragm to improve respiratory function, weakly relaxes the coronary arteries, peripheral blood vessels and bile duct smooth muscles, slightly increases myocardial contractility and has a diuretic effect.

More

It has a direct relaxant effect on respiratory smooth muscle, inhibits phosphodiesterase to increase the intracellular cAMP content, achieves bronchial dilation partly by releasing endogenous adrenaline and norepinephrine, can enhance the contractility of the diaphragm to improve respiratory function, weakly relaxes the coronary arteries, peripheral blood vessels and bile duct smooth muscles, slightly increases myocardial contractility and has a diuretic effect.

317-34-0 10
Aminophylline Injection
Aminophylline
Name Description Content CAS NO. Registered Holders
Aminophylline

It has a direct relaxant effect on the smooth muscles of the respiratory tract; it increases the intracellular cAMP content by inhibiting phosphodiesterase; its bronchodilator effect is partly due to the release of endogenous adrenaline and norepinephrine; as a purine receptor blocker, it can counteract the contractile effect of adenine and other substances on the respiratory tract; it enhances the contractility of the diaphragm to improve respiratory function; it has a weak effect of relaxing the smooth muscles of the coronary arteries, peripheral blood vessels and bile ducts; it slightly increases contractility and has a slight diuretic effect.

More

It has a direct relaxant effect on the smooth muscles of the respiratory tract; it increases the intracellular cAMP content by inhibiting phosphodiesterase; its bronchodilator effect is partly due to the release of endogenous adrenaline and norepinephrine; as a purine receptor blocker, it can counteract the contractile effect of adenine and other substances on the respiratory tract; it enhances the contractility of the diaphragm to improve respiratory function; it has a weak effect of relaxing the smooth muscles of the coronary arteries, peripheral blood vessels and bile ducts; it slightly increases contractility and has a slight diuretic effect.

317-34-0 10
Neomycin Sulfate Injection
Neomycin Sulfate
Name Description Content CAS NO. Registered Holders
MICRONOMICIN SULFATE

This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.

More

This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.

66803-19-8 3
Neomycin Sulfate Injection
Neomycin Sulfate
Name Description Content CAS NO. Registered Holders
MICRONOMICIN SULFATE

This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are all resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.

More

This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are all resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.

66803-19-8 3
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.